Form 4: Lyra Therapeutics Executive Chair Harlan Waksal Receives 128,333 Shares Upon Milestone Achievement

Harlan Waksal, Executive Chair of Lyra Therapeutics, acquired 128,333 shares of common stock following the achievement of a performance-based milestone.

Summary

• Harlan Waksal, the Executive Chair of Lyra Therapeutics, has acquired 128,333 shares of common stock.
• These shares were earned as part of a performance-based restricted stock unit (PSU) agreement.
• The PSU was granted on March 21, 2024, for a potential total of 385,000 shares, contingent on achieving certain milestones.
• On December 9, 2024, Lyra Therapeutics determined that Milestone 1 of the PSU was achieved, resulting in 128,333 PSUs being earned.
• The earned PSUs will vest on January 31, 2028.
• The PSUs have no expiration date.

Sentiment

Score: 7

Explanation: The document reflects a positive event (milestone achievement) and standard executive compensation practices, indicating a stable and progressing company.

Positives

• The achievement of Milestone 1 indicates progress in the company's performance goals.
• The vesting of shares incentivizes the Executive Chair to continue driving company success.

Industry Context

This type of equity-based compensation is common in the biotech industry to align executive interests with company performance and shareholder value.

Comparison to Industry Standards

• Performance-based equity awards are a standard practice in the biotechnology industry, often tied to clinical trial milestones, regulatory approvals, or commercialization targets.
• Companies like Amgen, Regeneron, and Biogen also use similar incentive structures to motivate their executives.
• The vesting schedule of January 31, 2028, is a typical long-term incentive approach, designed to retain key personnel and encourage sustained performance.

Stakeholder Impact

• Shareholders may view the milestone achievement positively, as it indicates progress towards company goals.
• Employees may be motivated by the company's progress and the alignment of executive incentives with company performance.

Key Dates

Keywords

Lyra Therapeutics, Harlan Waksal, Performance-based Restricted Stock Units, PSU, Share Acquisition, Milestone Achievement, Executive Compensation, Stock Vesting